Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Comment by eric40on Dec 10, 2020 8:01pm
198 Views
Post# 32085400

RE:RE:Rock and Roll

RE:RE:Rock and Roll Redeska approval is big awaited news that will a a dramatic impact on 2021 and future revenu. As a generic heparin, the only one available, provinces where it is mandatory to buy generic first if available will have to bur Valeo's generic heparine (Redeska). And I bet that with covid impact on province's deficit,  the rest of the provinces where it is not madatory yet will make it madatory soon enough to buy generic first so the 200 millions heparin market should shift largely to generic so Valeo sales projections for Redeska will probably be 2X to 6 X mid term IMHO.

I believe the short sales will be much higher on the next report mid december as short seller had a good opportunity with the tax loss season to sell the news

People who bought higher than 1.40$ to 1.50$ might want to take a loss. 

If I am right, the january effect should be quite good for Valeo IMO once the last trading days of 2020 will be done and shorts will have cover. 

We will see if that make sense on the next short report on december 16 unless shorts covert by then (a short short sale!)

Anyway, I am bullish more than ever now with Redeska approval.

GLTA
<< Previous
Bullboard Posts
Next >>